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ABSTRACT 
Objective: Hypercholesterolemia (HC) was frequently associated with oxidative stress, and release of inflammatory cytokines is to determine the 
hypolipidemic effects of sulphated polysaccharides from seaweed Ulva fasciata algal extracts through measuring the activities of some parameters 
related to liver and kidney functions in the serum of hypercholesterolemic rats as compared to normal one.  
Methods: Different groups of rats were administered a high cholesterol diet. Liver and kidney functions, inflammatory cytokines (TNF-α, CRP, MPO and 
IL-10), oxidative stress (GSH, MDA and NO), in addition to cell adhesion molecules (ICAM-1 and VCAM-1) were assessed before and after treatment with 
the algal polysaccharides. In addition, histological examination of liver and kidney were performed to confirm the biochemical findings.  
Results: The obtained results showed that oxidative stress and inflammatory markers associated with hypercholesterolemia were significantly 
increased in HC-rats. The histopathological examination of liver and kidney demonstrated severe degeneration with diffuse vacuolar degeneration, 
necrosis and the presence of fatty droplets. In addition; nephron-histological examination revealed, mild glomerular injury with mild vascular and 
inflammatory changes. Treatment with the algal sulphated polysaccharides effectively improved these disorders and diminished the formation of 
fatty liver, as well as renal dysfunction more than the reference drug; fluvastatin.  
Conclusion: It could be concluded that the consumption of UFP (Ulva fasciata polysaccharides), may be associated with attenuation of 
inflammatory markers, amelioration of fatty liver and improvement of renal dysfunction, that in turn lead to counteract hypercholesterolemia and 
its related disorders; such as obesity, and heart disease. 
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INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) which can be induced by a 
high fat diet is one of the most common liver diseases around the 
world. Hepatic lipid accumulation, the major hallmark of NAFLD, 
results from an imbalance between lipid acquisition and lipid 
disposal [1]. 
Cholesterol metabolism is balanced by cholesterol absorption and 
endogenous cholesterol synthesis with excretion of bile acids and 
biliary cholesterol [2]. The liver plays a central role in maintaining 
lipid homeostasis through LDL-C clearance and HDL-C recruitment 
[3]. Hepatic cholesterol secretion into plasma occurs principally 
through the formation and secretion of VLDL-C [4], while the biliary 
pathway represents the major route for the removal of hepatic 
cholesterol from the body, through both the direct secretion of 
cholesterol itself as well as the conversion of cholesterol into 
primary bile acids [4, 5].  
Non-alcoholic hepatic steatosis or fatty liver is the abnormal 
accumulation of triglycerides in the cytoplasm of hepatocytes. As it 
was found to increase the vulnerability of the liver to progression to 
nonalcoholic steatohepatitis and advanced stages of liver disease [6], 
hepatic steatosis is no longer regarded as a relatively benign 
condition. NAFLD involves fat in the liver and nonalcoholic 
steatohepatitis (NASH), progressing from hepatic steatosis with 
lobular inflammation to ballooning degeneration, fibrosis, and 
eventually to cirrhosis [7]. 
There is no doubt that lipid metabolic disorder is one of the most 
critical and basic pathogenesis of NAFLD. In spite of its high 
prevalence, up till now there is no proven effective treatment for 
NAFLD [8, 9]. So, the ability to alleviate or prevent these disorders 
would have a significant effect on anti-NAFLD formation. 
As cholesterol homeostasis is maintained by cholesterol absorption 
and endogenous cholesterol synthesis, here, it should also be 
emphasized on HMG-CoA reductase, which is a major enzyme to 
control the rate of cholesterol synthesis [4]. Fatty acid synthase 
(FAS) is an enzyme catalyzing de novo fatty acid synthesis. Studies 
have reported that increased FAS expression is strongly associated 
with fatty liver [10, 11].  
Obesity and insulin resistance can lead to an increase in free fatty 
acid (FFA) uptake by hepatocytes and also an increase in hepatic 
FFA synthesis, which causes an imbalance between uptake/ 
synthesis and oxidation/export of fatty acid and accumulation of 
triglycerides in hepatocytes. FFA overload in hepatocytes can lead to 
greater production of reactive oxygen species both by over-reduced 
mitochondrial electron transport chains (O2•−and H2O2) and 
increased FFA oxidation by peroxisomes and microsome (H2O2) [12]. 
Injury of hepatocytes by oxidative stress can subsequently lead to 
death by necrosis or apoptosis. Lipid peroxidation products and 
cytokines are released from dead hepatocytes, and some can trigger 
the activation of Kupffer cells and hepatic stellate cells, leading to 
inflammation and fibrosis of the liver [13]. 
Previous studies have shown a close relationship between NAFLD 
and atherosclerosis [14-16]. Accumulation of lipids in the non-
adipose tissues can cause cellular injury and dysfunction as seen in 
hepatic steatosis and atherosclerosis [17]. Cellular lipid homeostasis 
is regulated by the balance between influx, efflux, synthesis, and 
catabolism of lipids. An imbalance in these pathways can result in 
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lipid accumulation in macrophages, mesangial cells, vascular smooth 
muscle cells, and other cell types causing tissue damage. 
Numerous studies show that dyslipidemia accompanies and 
aggravates renal disease [18, 19]. Hypercholesterolemia, for 
example, has been shown to elicit renal dysfunction, inflammation, 
and fibrosis, partly mediated by increased oxidative stress in animal 
models [20]. 
In fact, chronic kidney disease (CKD) occurred in animals that 
exhibit accumulation of cholesterol in the remnant kidney and artery 
wall [21]. This is associated with driven by oxidation of lipids and 
lipoproteins. The prevailing oxidative stress in CKD results in 
accumulation of oxidized lipids and other molecules in the body 
fluids and tissues. Macrophages and mesangial cells in the diseased 
kidney avidly engulfed oxidized lipids and lipoproteins. 
Accumulation of lipid in the renal tissue can promote progression of 
glomerular and tubulointerstitial lesions in metabolic syndrome, and 
in chronic glomerular diseases [22]. 
Traditionally, assessments of liver and kidney function and injury 
are based on static tests, such as alkaline phosphatase (ALP), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), albumin 
(ALB), total protein (TP), and bilirubin, while urea and creatinine 
levels determination was performed to assess kidney function.  
Thus, the present study aims to evaluate the cholesterol-lowering 
effect of sulphated polysaccharides (SP) in high-fat diet-induced 
hypercholesterolemia in rats. 
MATERIALS AND METHODS 
Collection of the algal sample 
Ulva fasciata, belongs to the family Ulvaceae, was collected in June 
2010 from Abukir, Alexandria. The collected samples of alga were 
cleaned of epiphytes, barnacle, gastropod and other contaminants at 
the site. After washing thoroughly with tap water, the samples were 
air dried at room temperature in the shade, milled coarsely 
powdered and stored in polyethylene plastic bags in a dry place. 
Herbarium specimens of the alga were identified by Dr. Shaalan S. A., 
Professor of Phycology, Faculty of Science; Alexandria University. 
Preparation of U. fasciata polysaccharides (UFP) crude extracts 
Chemical extraction 
Air-dried alga was soaked in 30% volume (w/v) of distilled water 
and kept overnight at 4 to 5 °C. Then the material was stirred well 
and allowed it to return to room temperature. The cold water extract 
was first filtered through muslin cloth and then with filter paper. 
The process was repeated till complete exhausted of polysaccharide 
(negative molish test). The extract was concentrated to 1/10 of its 
original volume under reduced pressure at 40 °C using rotary 
evaporator with vacuum (BÜCHI Rotavapor R 200), and precipitated 
by the addition of 4-fold volume of 95% (v/v) ethanol, centrifuge at 
3000 rpm for ten minutes. The algal residue of cold water was 
soaked in sufficient distilled water and heated at 100 °C for 3h and 
hot water extract was obtained following the same procedure used 
for the cold water extract. The precipitate was washed twice with 
absolute ethanol; the dried by freeze dryer to obtain a crude 
polysaccharide extracts (cold and hot extracts) then keeps in the 
refrigerator for chemical and biological investigation [23]. The yields 
of polysaccharides of Ulva fasciata were calculated on the basis of 
the dry weight of algal sample (w/w).  
Chemicals 
All chemicals and reagents were purchased from Biodiagnostic 
Company for diagnostic and research reagents, Egypt. Reference 
drug (Fluvastatin) was purchased from NOVARTIS Pharmaceuticals. 
ELISA kits were provided by Uscn (U. S. A.) for CRP and Invitrogen 
(U. S. A.) for TNF-α. 
Induction of hypercholesterolemia 
Hypercholesterolemia was induced in rats according to the method 
of Adaramoye et al. [24], by feeding rats high-fat diet, cholesterol 
was orally administrated at a dose of (30 mg/0.3 ml olive oil/1 kg 
animal) five times a week for twelve consecutive weeks, lard fat was 
mixed with normal diet (One kilogram of animal lard was added to 
5Kgs of normal diet), the occurrence of hypercholesterolemia was 
determined by measuring the lipid profile; total cholesterol (TC), 
low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triacylglycerol (TG), the 
hypercholesterolemic rats were only used. 
Doses and routes of administration 
 Negative cold extract: Normal rats given U. fasciata cold extract 
at a dosage of 175 mg/kg body weight dissolved in distilled water 
for 4 w, this dose was calculated from the therapeutic dose for rats 
[23].  
 Negative hot extract: Normal rats given U. fasciata hot extract at 
a dosage of 175 mg/kg body weight dissolved in distilled water for 4 
w. 
 Hypercholesterolemic (HC) rats received an oral dose of cold 
UFP extract; 175 mg/kg body weight dissolved in distilled water 
daily for 4 w. 
 Hypercholesterolemic (HC) rats received an oral dose of hot UFP 
extract at a dose of 175 mg/kg body weight dissolved in distilled 
water daily for 4 w.  
 Hypercholesterolemic (HC) rats received an oral dose of 2 
mg/kg body weight dissolved in distilled water of the anti-
hypercholesterolemic reference drug. 
Experimental design 
Rats: A total of 105 Male Wister rats weighing 120±10 gm, were 
provided from the animal house of the National Research Center 
(NRC), and housed in a temperature-controlled environment (26-29 
°C), in steel mesh cages on wood-chip bedding, with a fixed 
light/dark cycle for two weeks as an acclimatization period with free 
access to water and food ad libitum. The present study was approved 
by the Ethical Committee of the National Research Center (NRC), 
Egypt, which provided that the animals will not suffer at any stage of 
the experiment. 
Animals were randomly divided into seven equally sized groups of 
15 rats each [n=15] as follows: Group 1: Normal controls, given a 
normal diet and distilled water. Group 2: Negative cold extract 
controls: Normal rats given cold UFP extract. Group 3: Negative hot 
extract controls: Normal rats given hot UFP extract. Group 4: 
Hypercholesterolemic (HC) positive control rats. Group 5: HC-rats 
received an oral dose of cold UFP extract. Group 6: HC-rats received 
an oral dose of hot UFP extract. Group7: HC-rats received an oral 
dose of the anti-hypercholesterolemic reference drug; fluvastatin.  
Blood collection and tissue sampling 
By the end of the experiment (4weeks), the animals of different 
groups fasted for 12 h, weighted then blood samples were collected 
from the sublingual vein, left to coagulate at room temperature and 
centrifuged at 3000 rpm for 15 min. The clear, non-hemolyzed, 
supernatant sera were quickly removed and kept at-80 °C till used 
for biochemical investigations of lipid profile, liver function, kidney 
function parameters and inflammatory markers (TNF-α, MPO, IL-10 
and CRP). Then animals sacrificed using diethyl ether anesthesia, 
and liver tissue were rapidly excised and accurately weighed. Each 
liver was then cut into two parts; one part was immediately 
preserved in 10% buffered formaline at 4 °C for histological 
examination; the reminder of the liver was stored at-80 °C until 
biochemical analysis. Also, the kidney tissue was rapidly excised; a 
part was cut and immediately preserved in 10% buffered formaline 
at 4 °C for histological examination. 
Preparation of tissue homogenate 
The liver tissue was accurately weighed (0.5 g from each liver) and 
homogenized in 5 ml phosphate buffer using (pH 7.4) electrical 
homogenizer. To prepare 10% (w/v) clear tissue homogenate for 
determination of malondialdehyde (MDA), non-enzymatic antioxidant 
defense system; reduced glutathione (GSH) and nitric oxide (NO). 
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Serum total cholesterol (TC), serum triacylglycerol (TGs), serum 
HDL-C concentration were determined colorimetrically by the 
methods of Allain et al. [25], Fassati and Prencipe [26], Lopez-Virella 
et al. [27]. Serum LDL-C concentration was calculated by 
Friedewald's formula [28]. Serum very low-density lipoprotein 
(VLDL-C) was determined according to Norbert [29].  
Liver function assay 
Both alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), activities were assayed according to the method 
of Reitman and Frankel [30]. Alkaline phosphatase (ALP) activity, 
Total bilirubin (TB), Total protein (TP), Albumin (alb) and Glucose 
were determined colorimetrically according to the methods of 
Belfield and Goldberg [31], Walters and Gerade [32], Bradford [33], 
Doumas et al. [34] and Trinder [35].  
Kidney function assay 
Serum urea and creatinine concentrations were estimated according 
to the methods of Fawcett and Scott [36] and Schirmeister et al. [37].  
Estimation of antioxidant markers 
Lipid peroxides were assessed in the liver homogenate as 
thiobarbituric acid reactive substances, malondialdehyde (MDA) 
according to the method of Satoh et al. [38]. The level of hepatic 
glutathione (GSH) was assayed in liver homogenate using the 
method of Beutler et al. [39]. Liver nitric oxide (NO) was determined 
according to the method of Montgomery and Dymock [40]. 
Estimation of cell adhesion molecules 
Rat soluble Intracellular Adhesion Molecule-1 (s-ICAM-1) concentrations 
and rat soluble Vascular Cell Adhesion Molecule-1 (s-VCAM-1), were 
determined using Enzyme-linked Immuno Sorbent assay (ELISA). 
Estimation of serum inflammatory markers 
In vivo quantitative measurements of MPO, IL-10 TNF-α and CRP 
were performed by ELISA; a sandwich enzyme Immunoassay. 
Histopathological analysis 
Liver and kidney slices were fixed instantaneously in buffer neutral 
formalin (10%) for 24 h for fixation then processed in automatic 
processors, embedded in paraffin wax (melting point 55-60 o C) and 
paraffin blocks were obtained. Sections of 6 μm thicknesses were 
prepared and stained with Haematoxylin and Eosin (H&E) stain [41]. 
The cytoplasm stained shades of pink and red and the nuclei gave a 
blue color. The slides were examined and photographed under a 
light microscope at a magnification power of x150. 
Statistical analysis 
Data were analyzed by comparing values for different treatment 
groups with the values for individual control. All data were 
expressed as mean±SD of 15 rats in each group. Significant 
differences between the groups were statistically analyzed using 
SPSS computer program; one-way analysis of variance (ANOVA) 
combined with Student T-test. Values were considered significant 
when P value ≤ 0.05 and highly significant at P ≤ 0.001. 
RESULTS 
The current study is designed to examine the anti-
hypercholesterolemic, antioxidative, anti-inflammatory and anti-
NAFLD activities of green alga U. fasciata:  
Antihyperlipidemic activity in rats 
Lipid profile 
As compared to normal control rats, feeding rats with cholesterol-
enriched diet for 12-weeks gave rise to a highly significant elevation 
in serum total cholesterol (81.38%), total lipids (63.74%) and 
triacylglycerol (176.30%).  
Oral supplementation of cold and hot SP algal extract resulted in an 
insignificant change in the levels of total serum lipids by 7.02, and 
14.03% respectively, TC by 3.72, and 2.84%, respectively and TG by 
4.34 and 14.42%, respectively. The same for fluvastatin-treated HC 
rats which showed insignificant change by 8.77% and 13.36% 
respectively for serum total lipids and TC, except for a highly 
significant decrease in TG (85.75%) (P ≤ 0.05) (table 1). 
It was obvious that serum HDL-C level was highly significantly 
decreased in the HC-rats (85.74%), whereas serum LDL-C and VLDL-
C levels of HC-rats were significantly augmented, as compared to 
normal control group with percentages amounting to 323.86 and 
175.21%, respectively (table 1). Treatment of HC-rats with cold and 
hot SP extracts and fluvastatin showed a significant decrease in the 
serum LDL-C and VLDL-C with percentages decrease reached to 
62.56 and 3.99%, respectively for cold UFP extract. Treatment of HC-
rats with hot extract recorded the insignificant change of LDL-C 
(19.63%) and VLDL-C (14.71%). Fluvastatin treatment showed 
percentages decrease of 23 and 85.50%, respectively for LDL-C and 
VLDL-C, as compared to normal control rats. However, HDL-C level 
showed insignificant change (P ≤ 0.05) amounting to 12.69, 9.55 (P≤ 
0.001) and 3.20%, respectively for cold, hot SP extracts and fluvastatin.  
As compared to atherogenic HC-group; treatment of HC-rats with 
cold and hot UFP extracts or fluvastatin showed, marked reduction 
in TC, TG and total lipids levels, with percentages decrease of 42.81, 
62.24, and 34.64 %, respectively for cold extract and by 46.43, 69.03, 
and 30.36%, respectively for hot extract, while fluvastatin showed 
mild percentages decrease reached to 37.50, 32.77 and 33.57%, 
respectively. Concerning lipoproteins, treatment of atherogenic rats 
showed a significant decrease in LDL-C and VLDL-C levels with 
percentages decrease of 61.65 and 62.2%, respectively for cold UFP, 
and 81.04 and 69.01 % (P≤ 0.001), respectively for hot UFP. 
Fluvastatin treatment showed percentages significant decrease 
reached to 70.98 and 32.60%, respectively and in contrast, HDL-C 
level was highly significantly increased (P ≤ 0.05) in reached to 
512.36 and 578.88%, respectively for cold SP extract and fluvastatin 
respectively, and 668.31 for hot UFP (P≤ 0.001). 
The effects of UFP (cold and hot extracts) on liver enzymes 
activity and TB 
As compared to normal control healthy rats, high-fat fed rats (HC) 
gave rise to a highly significant increase in liver function enzymes; 
AST, ALT, ALP and TB by 67.67, 40.97, 115.29 and 40.91%, 
respectively. AST demonstrated a significant increase in HC-rats 
treated with cold UFP by 34.07% and fluvastatin by 42.22%, while 
the insignificant change in those treated with hot UFP by 2.89%. For 
ALT, an insignificant change was noticed for HC-rats treated with 
both cold UFP by 6.25% and hot UFP by 7.64%, except for a 
significant increase in ALT level in HC-fluvastatin treated rats by 
33.34%. Concerning ALP, HC-cold UFP treated rats demonstrated a 
slight significant increase by 20.00%, and also, HC-fluvastatin treated 
rats showed a slight significant decrease of 27.06%, while HC-hot UFP 
treated rats normalized its level. Whereas TB slightly increased by 
15.15 and 21.21% for HC-hot UFP and HC-fluvastatin treated rats and 
insignificant change for HC-cold UFP rats (P ≤ 0.05) (table 2).  
By comparing to HC-group, UFP treatment showed significant 
decrease in serum AST, ALT, ALP enzyme activities and TB by 20.04, 
24.63, 44.26 and 29.03%, respectively for cold UFP, while it was 
38.64, 23.64, 48.63 and 18.28%, respectively for hot UFP, while for 
fluvastatin; it recorded AST (15.18%) and TB (13.98%), and ALP 
(40.98%), while insignificant change for ALT (5.4%), (P≤ 0.001).  
The effects of UFP (cold and hot extracts) on total protein (TP) 
content and albumin (ALB) level 
The present study reveals significant lower levels of total protein 
(TP) and albumin in rats of high cholesterol diet as compared to 
normal controls. HC-rats showed significant reduction in TP content 
and ALB level by 14.76 % and 27.12 %, respectively as compared to 
normal control. Treatment of HC-rats with cold and hot UFP extracts, 
as well as, reference drug fluvastatin normalized ALB level and 
restored the protein content to control levels (table 3). 
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As compared to HC-groups, UFP treatment showed a significant 
increase of total protein (TP) content and ALB level; by 14.30 and 
34.88% respectively for cold SP extract, 13.70 and 35.56%, 
respectively for hot SP extract, and 12.67and 41.86% for fluvastatin. 
The effects of UFP (cold and hot extracts) on serum blood 
glucose level (pancreatic function) 
As compared to normal control rats, blood glucose level of 
hypercholesterolemic rats (HC) was highly significantly increased by 
a percentage of 59.72 % (P≤0.001).  
Treatment of HC-rats with cold, hot extracts and reference drug 
restored blood glucose to near normal level and showed 
insignificant change by 1.26, 6.71, and 3.06 %, for cold UFP, hot UFP 
and fluvastatin respectively. With respect to, the obvious change in 
glucose after treatment with SP of cold and hot algal extracts as well 
as fluvastatin, UFP treatments of HC-rats showed significant 
reductions in blood glucose level by 38.18, 41.59 and 35.48%, 
respectively for cold and hot extracts and fluvastatin, as compared to 
HC-groups (table 3). 
The non-enzymatic antioxidant effect of UFP (cold and hot extracts) 
HC-group recorded a highly significant reduction in GSH level by 
60.34%. However, MDA, showed a highly significant elevation of 
85.43% and, it also exhibits a highly significant elevation of hepatic 
NO concentration, by 300.29% (P≤ 0.001), as compared to normal 
controls. Treatment of HC-rats with cold SP and hot SP algal extracts 
and fluvastatin normalized liver GSH level and, while NO 
concentration showed a significant increase by 33.31, 22.23 and 
67.35% for cold SP and hot SP and fluvastatin respectively. 
Concerning MDA level, it also recorded a significant increase by 
41.56, 27.81 and 32.12%, for cold SP, hot SP and fluvastatin 
respectively, as compared to normal control (table 4).  
Comparing to HC-rats, UFP treatments showed a significant increase 
in GSH concentration with the percentage of 134.78, 126.09 and 
147.83%, respectively for cold and hot SP extracts or fluvastatin. On 
the other hand, MDA achieved significant reduction by 23.66, 31.07 
and 28.75%, respectively for cold, hot extracts as well as fluvastatin 
reference drug, and it showed marked increase in NO level achieved 
significant decrease; 38.95, 69.46 and 58.19%, respectively for cold, 
hot SP extracts as well as fluvastatin reference drug. 
Anti-inflammatory effect of UFP 
From the manipulated data (table 5), High fat diet–rats showed 
significant increase in pro-inflammatory cytokines; TNF-α (73.19%) 
and CRP (61.52%), MPO (10.94%), and in contrast significant 
decreases in anti-atherogenic cytokine IL-10 (35.62%) was recorded 
as compared to normal control rats (P ≤ 0.05). 
As compared to normal control, treatment of HC-rats with both cold 
and hot SP extracts and fluvastatin drug showed CRP recorded 
significant increase by 24.02, 17.58 and 35.16%, respectively. MPO 
was slightly decreased by 8.15, 3.63 and 4.95%, for cold and hot UFP 
and fluvastatin, respectively. In addition, a significant increase was 
detected in TNF-α reached to 44.06, 41.65 and 61.78%, respectively; 
with cold and hot UFP and fluvastatin drug administered for 30 d 
post high fat diet (P ≤ 0.05). In contrast, Treatment of HC-rats 
showed a significant decrease in IL-10 level amounting to 16.26% 
for cold UFP, 23.75% for hot UFP and 13.65% for fluvastatin drug. 
There were significant positive correlations between hyperlipidemia 
with TNF-α, MPO, CRP and IL-10 as shown in (table 5). 
As compared to atherogenic rats (HC), treatment of HC-rats with 
cold and hot extracts or fluvastatin significantly decreased 
atherogenic inflammatory markers; CRP, MPO and TNF-α with 
percentages decrease of 21.04, 17.21 and 16.82% respectively for 
cold extract, while hot extract recorded 27.21, 13.13 and 18.21%, 
respectively, and fluvastatin showed 16.32 (CRP) and 14.32 (MPO), 
while insignificant change for TNF-α. On the other hand, a significant 
increase (P ≤ 0.05) was demonstrated in anti-atherogenic marker IL-
10 reached to 30.08, 18.45 and 34.13, respectively for cold and hot 
SP extracts and fluvastatin respectively. 
Effect of UFP extracts on endothelial dysfunction 
Soluble adhesion molecules 
The atherogenic HC-rats showed significantly increased in serum 
ICAM-1 (9.67%) and VCAM-1(36.09%) as compared to the negative 
control group (P ≤ 0.05), (table 6). 
As compared to the negative control group (P ≤ 0.05), treatment by 
both algal extracts and fluvastatin normalized serum ICAM-1, on the 
other hand, VCAM-1 was slightly increased by 26.15% for cold UFP, 
23.34% for hot UFP and 28.83 for fluvastatin. 
 
Table 1: Effects of cold and hot UFP extracts and fluvastatin supplementations on serum lipid profile in different therapeutic groups 













mean±SD 55.63±10.85 23.72±8.96 1000±52.6 19.66±9.24 31.21±1.48 4.76±1.79 
Negative 
Cold extract 
mean±SD 54.03±5.45 24.21±5.49 1105.26±52.65 22.07±2.69 27.25±4.77 4.86±1.07 
% Change to 
control 
2.88 2.07 10.53 12.26 12.69 2.10 
Negative 
Hot extract 
mean±SD 57.65±8.28 24.84±5.19 1105.26±105.25 20.1±5.10 27.74±3.09 4.96±1.02 
% Change to 
control 
3.63 4.72 10.53 2.24 11.12 4.20 
HC-rats mean±SD 100.9±11.24*  65.54±7.05* 1637.43±96.64* 83.33±8.68*** 4.45±1.48* 13.10±1.40* 
% Change to 
control 
81.38 ↑ 176.30 ↑ 63.74 ↑ 323.56 ↑ 85.74 ↓ 175.21 ↑ 
HC-Cold 
extract 
mean±SD 57.7±6.23** 24.75±1.90** 1070.2±60.79** 31.96±12.05*,** 27.25±2.27** 4.95±0.38*,** 
% Change to 
control 
3.72 ↑ 4.34 ↑ 7.02 ↑ 62.56 ↑ 12.69 ↓ 3.99 ↑ 
%change to HC 42.81 ↓ 62.24 ↓ 34.64 ↓ 61.65 ↓ 512.36 ↑ 62.21 ↓ 
HC-Hot 
extract 
mean±SD 54.05±5.43** 20.3±3.4** 1140.33±80.40** 15.80±3.30** 34.19±1.50*** 4.06±0.65** 
% Change to 
control 
2.84 ↓ 14.42 ↓ 14.03 ↑ 19.63 ↓ 9.55 ↑ 14.71 ↓ 
%change to HC 46.43 ↓ 69.03 ↓ 30.36 ↓ 81.04 ↓ 668.31 ↑ 69.01 ↓ 
HC-
Fluvastatin 
mean±SD 63.06±8.30** 44.06±8.95*,** 1087.73±80.40** 24.18±7.99*,** 30.21±2.27** 8.83±1.79*,**  
% Change to 
control 
13.36 ↑ 85.75 ↑ 8.77 ↑ 23 ↑ 3.20 ↓ 85.50 ↑ 
%change to HC 37.50 ↓ 32.77 ↓ 33.57 ↓ 70.98 ↓ 578.88 ↑ 32.60 ↓ 
(TG): Triglycerides and (TC): Total cholesterol, (LDL-C): low-density lipoprotein cholesterol; (HDL-C): high-density lipoprotein cholesterol; (VLDL-
C): very low-density lipoprotein cholesterol. Data presented as mean±SD, n=15 for each treatment group, (*) is significant to control normal rats at 
P ≤ 0.05, (**) is significant to HC positive control at P ≤ 0.05, (***) is highly significant at P ≤ 0.001. 
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In comparison with atherogenic HC-rats, treatment with cold and 
hot UFP extracts as well as fluvastatin, both CAMs were slightly 
reduced by 5.43 and 7.31%, respectively for cold extract, by 5.91 and 
9.37% respectively for hot extract, whereas fluvastatin showed 
percentages decrease reached to 7.15 and 5.34%, respectively. 
The effects of UFP (cold and hot) on serum urea and creatinine 
levels 
The effects of hypercholesterolemia on renal function were assessed 
through measuring serum total urea and creatinine; high-fat diet 
intake caused highly significantly elevated levels of serum total urea 
and creatinine by 193% and 40%, respectively as compared to 
normal rats (p≤ 0.05), (table 7). 
As compared to normal controls, cold SP and hot SP algal extracts 
and fluvastatin-treated HC-rats showed a significant increase in urea 
by 21.48, 16.13 and 19.35%, respectively.  
Concerning, creatinine, it recorded insignificant change with the SP 
of cold UFP by 7%, while it showed nearly the same percentage of 
decrease 4%, with the hot extract and fluvastatin treatments. 
As compared to HC-group, treatment of HC-rats with cold, hot 
extracts and fluvastatin showed significant decrease in total urea 
and creatinine with percentages decrease of 58.54 and 33.57%, 
respectively for cold extract-treated HC-rats, while hot extract-
treated HC-rats recorded 60.37and 31.43%, respectively, and 59.26 
and 31.43%, respectively for fluvastatin-treated HC-rats. 
 
Table 2: Effects of UFP (cold and hot extracts) and fluvastatin supplementation on serum AST, ALT, ALP enzyme activities, and total 
bilirubin (TB) in HC-rats and different therapeutic groups 








Normal control mean±SD 38.42±2.11 63.97±2.03 42.50±2.17 0.66±0.03 
Negative 
Cold extract 
mean±SD 36.65±1.15 68.85±1.17 43.50±0.86 0.7±0.05 
% Change to control 4.61 7.63 2.35 6.06 
Negative 
Hot extract 
mean±SD 35.20±1.23 64.76±4.40 46.5±3.96 0.8±0.05 
% Change to control 8.38 1.23 9.41 21.21 
HC-rats mean±SD 64.42±1.34* 90.18±1.60* 91.50±3.46* 0.93±0.20 * 
% Change to control 67.67 ↑ 40.97 ↑ 115.29 ↑ 40.91 ↑ 
HC-Cold extract mean±SD 51.51±1.21*,** 67.97±2.03** 51.00±3.46*,** 0.66±0.03 ** 
% Change to control 34.07 ↑ 6.25 ↑ 20 ↑ 0.00 
%change to HC 20.04 ↓ 24.63 ↓ 44.26 ↓ 29.03 ↓ 
HC-Hot extract mean±SD 39.53±0.80** 68.86±2.34** 47.00±2.17** 0.76±0.03** 
% Change to control 2.89 ↑ 7.64 ↑ 10.59 ↑ 15.15 ↑ 
%change to HC 38.64 ↓ 23.64 ↓ 48.63 ↓ 18.28 ↓ 
HC-Fluvastatin mean±SD 54.64±0.38*,** 85.30±0.76* 54.00±3.77*,** 0.8±0.05*,** 
% Change to control 42.22 ↑ 33.34 ↑ 27.06 ↑ 21.21 ↑ 
%change to HC 15.18 ↓ 5.4 ↓ 40.98 ↓ 13.98 ↓ 
(ALT): Alanine aminotransferase; (AST): Aspartate aminotransferase; (ALP): Alkaline phosphatase; (TB): Total bilirubin. Data presented as 
mean±SD, n=15 for each treatment group. (*) is significant to control normal rats at P ≤ 0.05, (**) is significant to HC positive control at P ≤ 0.05. 
 
Table 3: Effects of UFP (cold and hot extracts) and fluvastatin supplementation on serum total protein (TP) content and albumin (ALB) 
level in addition to glucose level of HC-rats and different therapeutic groups 





Normal control mean±SD 38.8±0.61 5.9±0.12 87.00±2.96 
%change to HC 17.33 37.21 37.39 
Negative Cold extract mean±SD 38.00±0.23 5.8±0.05 86.83±4.87 
% Change to control 2.10 1.69 1.19 
%change to HC 14.91 34.88 37.51 
Negative Hot extract mean±SD 37.73±0.48 5.7±0.12 85.36±5.86 
% Change to control 2.76 3.39 1.89 
%change to HC 14.09 35.56 38.57 
HC-rats mean±SD 33.07±1.16* 4.3±0.15 * 138.96±3.92*** 
% Change to control 14.76 ↓ 27.12 ↓ 59.72 ↑ 
HC-Cold extract mean±SD 37.8±0.11 ** 5.8±0.17 ** 85.90±8.14** 
% Change to control 2.58 ↓ 1.69 ↓ 1.26 ↓ 
%change to HC 14.30 ↑  34.88 ↑  38.18 ↓ 
HC-Hot extract mean±SD 37.6±0.46 ** 5.7±0.21 ** 81.16±3.89** 
% Change to control 3.09 ↓ 3.39 ↓ 6.71 ↓ 
%change to HC 13.70 ↑  35.56 ↑ 41.59 ↓ 
HC-Fluvastatin mean±SD 37.26±0.43** 6.1±0.33** 89.66±4.87** 
% Change to control 3.97 ↓  3.39 ↑ 3.06 ↑ 
%change to HC 12.67 ↑ 41.86 ↑ 35.48 ↓ 
(TP): Total proteins, Data presented as mean±SD, n=15 for each treatment group. (*) is significant to control normal rats at P ≤ 0.05, (**) is 




Histopathological examination of negative control rat liver showed 
the normal histological structure of hepatic lobule and normal 
hepatocytes (fig. 1).  
Healthy rats treated with both cold and hot algal extracts showed 
normal hepatic lobular architecture with normal hepatocytes. No 
hydropic or steatosis changes were seen, and portal tracts were 
within normal limits, and no sign of fibrosis was detected (Figs. 2, 3). 
In HC-rats, the hepatic cords of rats were disorganized, and large 
numbers of liver cells were swollen and had undergone hydropic 
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degeneration. Different sizes of fat droplets and fatty degeneration 
of the liver were observed in the cytoplasm of hepatocytes from 
hyperlipidemic rats. Inflammatory cell infiltrations along with spotty 
and patchy necrosis of hepatocytes were also observed in the lobule 
and portal areas (fig. 4). Hepatocytes of HC rats showed severe 
degeneration with diffuse vacuolar degeneration and necrosis. 
Table 4: The antioxidant effect of UFP (hot and cold) extracts and fluvastatin supplementation on MDA, NO and GSH levels in liver tissue of 
HC-rats and different therapeutic groups. 
Groups                    Parameters GSH mg/g tissue MDA (LPO) nmol/g tissue NO mg/g tissue 
Normal control mean±SD 0.58±0.02 6.04±0.87 13.63±4.54 
Negative 
Cold extract 
mean±SD 0.56±0.05 6.06±0.57 27.26±4.54 
% Change to control 3.45 0.33 100 
Negative 
Hot extract 
mean±SD 0.55±0.04 5.98±0.61 22.72±4.54 
% Change to control 5.17 0.99 66.69 
HC-rats mean±SD 0.23±0.02*  11.20±0.17 * 54.56±9.12*** 
% Change to control 60.34 ↓ 85.43 ↑ 300.29 ↑ 
HC-Cold extract mean±SD 0.54±0.03** 8.55±0.93 *,** 18.17±4.54** 
% Change to control 6.90 ↓ 41.56 ↑ 33.31 ↑ 
%change to HC 134.78 ↑ 23.66 ↓ 38.95 ↓ 
HC-Hot extract mean±SD 0.52±0.05** 7.72±0.60 *,** 16.66±2.62** 
% Change to control 10.34 ↓ 27.81 ↑ 22.23 ↑ 
%change to HC 126.09 ↑ 31.07 ↓ 69.46 ↓ 
HC-Fluvastatin mean±SD 0.57±0.02*,** 7.98±0.67 *,** 22.81±4.54*,** 
% Change to control 1.72 ↓ 32.12 ↑ 67.35 ↑ 
%change to HC 147.83 ↑ 28.75 ↓ 58.19 ↓ 
(NO): Nitric oxide, (LPO): Lipid peroxide, (GSH): Glutathione reduced, Data presented as mean±SD, n=15 for each treatment group. (*) is significant 
to control normal rats at P ≤ 0.05, (**) is significant to HC positive control at P ≤ 0.05. (***) is highly significant at P ≤ 0.001. 
 
Table 5: The anti-inflammatory effect of UFP (hot and cold extracts) and fluvastatin supplementation on serum MPO, IL-10, TNF- and 
CRP levels in normal and hypercholesterolemic rats 
Groups                                    Parameters TNF-α (ρg/ml) CRP (ηg/ml) MPO (ρg/ml) IL-10 (ρg/ml) 
Normal control mean±SD 105.81±0.23 5.12±0.00 125.63±0.02 66.36±0.27 
Negative Cold extract mean±SD 110.27±0.20 5.29±0.01 123.63±0.00 64.40±0.25 
% Change to control 4.22 3.32 1.59 2.95 
Negative 
Hot extract 
mean±SD 107.27±0.19 5.67±0.01 128.60±0.01 65.27±0.18 
% Change to control 1.38 10.74 2.36 1.64 
HC-rats mean±SD 183.25±0.22 ** 8.27±0.015** 139.37±0.60* 42.72±0.24** 
% Change to control 73.19 ↑ 61.52 ↑ 10.94 ↑ 35.62 ↓ 
HC-Cold extract mean±SD 152.43±0.27*,** 6.53±0.04 *,** 115.39±0.01* 55.57±0.47 *,** 
% Change to control 44.06 ↑ 24.02 ↑ 8.15 ↓  16.26 ↓  
%change to HC 16.82 ↓ 21.04 ↓ 17.21 ↓ 30.08 ↑  
HC-Hot extract mean±SD 149.88±0.163 *,** 6.02±0.01 *,** 121.07±0.01* 50.6±0.41*,** 
% Change to control 41.65 ↑ 17.58 ↑ 3.63 ↓ 23.75 ↓ 
%change to HC 18.21 ↓ 27.21 ↓ 13.13 ↓ 18.45 ↑ 
HC-Fluvastatin mean±SD 171.18±0.14 *,** 6.92±0.01 * 119.41±0.32 * 57.3±0.22 *,** 
% Change to control 61.78 ↑ 35.16 ↑ 4.95 ↓ 13.65 ↓ 
%change to HC 6.95 ↓ 16.32 ↓ 14.32 ↓ 34.13 ↑ 
(MPO): Myeloperoxidase, (CRP): C-reactive protein, (TNF-α): Tumor necrosis factor-α, (IL-10): Interleukin-10. Data presented as mean±SD, n=15 
for each treatment group. (*) is significant at P ≤ 0.05 to control normal rats, (**) is significant to HC positive control at P ≤ 0.05. 
 
Table 6: The antioxidant effect of UFP (hot and cold) extracts and fluvastatin supplementation on VCAM-and ICAM-1 in HC rats and 
different therapeutic groups 
Groups                                                                                     Parameters ICAM-1 (ηg/ml) VCAM-1 (ηg/ml) 
Normal control mean±SD 251.40±0.21 12110.63±2.67 
Negative 
Cold extract 
mean±SD 244.73±0.32 13473.51±46.46 
% Change to control 2.65 11.25 
Negative 
Hot extract 
mean±SD 249.21±0.17 13237.07±33.06 
% Change to control 0.87 9.30 
HC-rats mean±SD 275.71±0.21 *  16482.26±85.32 * 
% Change to control 9.67 ↑ 36.09 ↑ 
HC-Cold extract mean±SD 255.99±0.32 ** 15276.97±84.07 ** 
% Change to control 1.83 ↑ 26.15 ↑ 
%change to HC 7.15 ↓ 7.31 ↓ 
HC-Hot extract mean±SD 259.41±0.26 ** 14937.60±55.31 ** 
% Change to control 3.19 ↑ 22.34 ↑ 
%change to HC 5.91 ↓ 9.37 ↓ 
HC-Fluvastatin mean±SD 260.75±0.21 ** 15302.6±74.63 ** 
% Change to control 3.42 ↑ 28.83 ↑ 
%change to HC 5.43 ↓ 5.34 ↓ 
(VCAM-1): Vascular cellular adhesion molecule-1, (ICAM-1): Intracellular adhesion molecule-1. Data presented as mean±SD, n=15 for each 
treatment group. (*) is significant to control normal rats at P ≤ 0.05, (**) is significant to HC positive control at P ≤ 0.05. 
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Table 7: Effect of UFP (hot and cold extracts) and fluvastatin supplementation, on kidney function tests (total urea and creatinine), of 
hypercholesterolemic rats and different therapeutic groups 




Normal control mean±SD 31.00±0.51 1.00±0.05 
Negative 
Cold extract 
mean±SD 30.00±0.57 0.93±0.03 
% Change to control 3.24 7 
Negative 
Hot extract 
mean±SD 28.00±0.57 1.00±0.05 
% Change to control 9.68 0 
HC-rats mean±SD 90.83±4.63 * 1.4±0.11* 
% Change to control 193 ↑ 40 ↑ 
HC-Cold extract mean±SD 37.66±1.45 *,** 0.93±0.08 ** 
% Change to control 21.48 ↑ 7 ↓ 
%change to HC 58.54 ↓ 33.57 ↓ 
HC-Hot extract mean±SD 36.00±0.57*,** 0.96±0.03 ** 
% Change to control 16.13 ↑ 4 ↓ 
%change to HC 60.37 ↓ 31.43 ↓ 
HC-Fluvastatin mean±SD 37.00±1.37*,** 0.96±0.03 ** 
% Change to control 19.35 ↑ 4 ↓ 
%change to HC 59.26 ↓ 31.43 ↓ 
Data presented as mean±SD, n=15 for each treatment group. (*) is significant to control normal rats at P ≤ 0.05, (**) is significant to HC positive 
control at P ≤ 0.05 
 
The effect of U. fasciata on hepatocyte cells of HC rats is presented in 
(fig. s: 5, 6). The hepatic cords were typically arranged and located in 
liver tissue near the central vein in the normal control (NC), HC, and 
HC+SP groups. Hepatic cells of HC rats treated with both cold and hot 
SP extracts were improved with fewer endothelium injuries and less 
fat vacuoles, showed a considerable reduction in the pathological 
changes and exhibited an almost normal fig. as the control and the 
hydropic degeneration of the hepatocyte disappeared. The circular fat 
droplets in the cytoplasm decreased significantly, and only minor 
inflammatory cell infiltration was observed in portal areas. 
Concerning fluvastatin drug, it was observed that liver recovery 
included decreased signs of fatty liver with few fatty vacuoles. 
Hepatic cells of HC-rats treated with fluvastatin were improved with 
fewer endothelium injuries and less fat vacuoles, (fig. 7). 
Kidney 
Normal control kidney (fig. 8), revealed normal histology of the 
glomerulus, well-spaced tubules and normal orientation of 
nephrons with adequate glomeruli. Similar results were obtained 
for cold and hot algal extracts administered to normal healthy rats 
(Fig.9, 10).  
Light microscopy observations of HC-rats revealed, mild 
glomerular injury with mild vascular and inflammatory changes, 
signs of moderate vascular congestion, mesangial hyperplasia 
and dilatation of vascular lumen with no evidence of fat deposits 
(mild glomerular change), moderate tubular damage, that is, 
desquamated and/or vacuolated tubular epithelial cells, was 
noted as well (fig. 11). 
 
  
Fig. 1: Micrograph of the liver of Control shows the architecture of a 
hepatic lobule. The central vein (CV) lies at the center of the lobule 
surrounded by the hepatocytes (HC) with strongly eosinophilic 
granulated cytoplasm (CY), and distinct nuclei (N). Between the strands 
of hepatocytes, the hepatic sinusoids are shown (HS) (H & E X 150) 
Fig. 2: Micrograph of the liver of rat traded with cold extract 
shows the normal structure of the hepatic lobule, (H & E X 
150). 
  
Fig. 3: Micrograph of liver of rat traded with hot extract shows 
normal structure of the hepatic lobule, (H & E X 150) 
Fig. 4: Micrograph of liver of HC shows fatty change of the hepatic 
lobule and hydropic degeneration (H & E X 150) 
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Fig. 5: Micrograph of liver of HC rat treated with cold extract shows 
reduction of the fatty change as compared with the 
hypercholesteremic one (H & E X 150) 
Fig. 6: Micrograph of liver of HC treated with hot extract shows 
normal structure of the hepatic lobule (H & E X 150) 
 
  
Fig. 7: Micrograph of liver of HC treated with the reference drug 
shows normal structure of the hepatic lobule. Notice the few fatty 
vacuoles (H & E X 150) 
 
Fig. 8: Micrograph of the kidney of Control rat showing normal 
structure of the glomeruli and the renal tubules. Notice that 
distal convoluted tubules (DCT) could be differentiated from the 
proximal convoluted tubules (PCT) as having larger and well-
defined lumina, less affinity to stain (H & E X 150) 
  
Fig. 9: Micrograph of kidney of rat treated with Cold Extract showing 
normal structure of the glomerulus and the renal tubules (H & E X 
150) 
Fig. 10: Micrograph of kidney of rat treated with hot Extract 
shows the normal structure of the glomerulus and the renal 
tubules (H & E X 150) 
  
Fig. 11: Micrograph of the kidney of HC rat showing hypotrophy of 
the glomerulus that associated with wide urinary space. Note the 
epithelial detachment of the renal tubules and cellular debris in the 
lumen of the tubules (H & E X 150) 
Fig. 12: Micrograph of kidney of HC-rat treated with Cold Extract 
showing normal structure of the glomerulus and the renal 
tubules (H & E X 150) 
 
  
Fig. 13: Micrograph of kidney of HC-rat treated with Hot Extract 
shows the normal structure of the glomerulus and the renal tubules 
(H & E X 150) 
Fig. 14: Micrograph of kidney of HC-rat treated with the 
reference drug (F) shows normal structure of the glomerulus and 
the renal tubules, (H & E X 150) 
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Treatment of HC-rats with algal extracts and fluvastatin showed, 
milder tubular injury, no glomerular or tubular alterations, no 
basement membrane thickening and fibrosis were discerned. 
Furthermore, normal histology of the glomerulus with well-spaced 
tubules, no congestion, and no inflammation was detected (fig. 12, 
13 and 14 respectively). 
DISCUSSION 
It is widely accepted that NAFLD is closely related to an excess 
intake of calories, obesity, and insulin resistance, and it is therefore 
considered as a hepatic manifestation of metabolic syndrome, [42, 
43]. Thus, the regulation of hepatic lipid metabolism including both 
lipogenesis and lipolysis should be emphasized for preventing 
dyslipidemia and the accompanying illness [44]. Similarly, in our 
own study, it was found that rats fed with (30 mg cholesterol/0.3 ml 
olive oil/kg animal) and 10% fat for 12 w developed 
hypercholesterolemia with elevated endothelial dysfunction 
markers (CRP, TNF-α, MPO and IL-10) and histological evidence of 
fatty deposits in liver cells. 
It was found that the cholesterol-enriched diet for 12-weeks 
resulted in a dramatic surge in serum total cholesterol (81.83%), 
total lipids (63.74%), and triacylglycerols (176.30%). Concerning 
lipoproteins, it was oblivious that, circulating serum HDL-C level 
(the good cholesterol) was significantly diminished (85.74%) in the 
HC-rats, whereas atherogenic lipoproteins; LDL-C (the bad 
cholesterol) and VLDL-C levels were significantly raised as 
compared to normal control group, thus providing a model for 
dietary hyperlipidemia. The increase of lipid parameters had been 
shown to be a strong risk factor for coronary heart diseases in many 
populations [45]. These results run in parallel with Jang et al. [46]. 
The high level of LDL-C found in hypercholesterolemic rats may be 
attributed to a down-regulation in LDL receptors by cholesterol and 
saturated fatty acids included in the diet [47, 48]. 
Therefore, treatment of hypercholesterolemic rats with UFP (U. 
fasciata cold and hot sulphated polysaccharide extracts) induced a 
significant marked decrease of serum total lipids, total cholesterol, 
triacylglycerols and LDL-C concentrations as compared to the 
positive control rats. Rats treated with both cold and hot algal 
extracts showed enhanced HDL-C level; which may be due to the 
ability of the extract to hasten the decomposition of free radical 
species generated during cholesterol administration [49]. 
The hypolipidemic effect of algal extracts might be due to galactose 
sugar in the hydrolysates of cold SP extract and fucose sugar in the 
hydrolysates of hot SP extract. In fact, dietary fiber are known to 
interfere with cholesterol absorption and enterohepatic bile 
circulation, resulted in depletion of hepatic cholesterol pools and 
reduce triacylglycerol levels by inhibition of hepatic lipogenesis [50].  
According to the previous report, there is also another type of anti-
hyperlipidemic mechanism: bile acid sequestrant mechanism. 
Polysaccharides can act as stimulators of bile acid synthesis. Most 
bile acids are reabsorbed in the small intestine and return to the 
liver so that the bile acid pool remains essentially constant. Bile acid 
sequestering resins act in the small intestine by interrupting the 
enterohepatic circulation and increasing the fecal excretion of bile 
acids so that fewer bile acids return to the liver. This increases the 
synthesis of bile acids, and the loss of bile acids is compensated for 
by oxidation of more hepatic cholesterol, the only precursor to bile 
acids, thereby decreasing the total blood cholesterol levels [51].  It is 
of a major importance the finding that HC rats treated with UFP had 
higher HDL level than untreated control animals fed with the high 
cholesterol diet. Indeed, HDL cholesterol serum concentrations were 
12.69%, 9.55% and 3.20% for cold, hot SP extracts and fluvastatin 
higher than the untreated control rats.  
It is noteworthy that LDL-C decrease induced by the UFP treatment 
overpowered the combined increase of HDL-C, therefore resulting in 
a decrease of biliary cholesterol. Indeed, a potential side-effect of 
HDL-C increase to be taken seriously is the formation of gallstone 
consecutive to the bile saturation in cholesterol [52].  
The liver plays a central role in maintaining lipid homeostasis as 
documented by Buzand and Mashek [3]. Hepatic cholesterol 
secretion into plasma occurs principally through the formation and 
secretion of VLDL-C [4], while the biliary pathway represents the 
major route for the removal of hepatic cholesterol from the body, 
through both the direct secretion of cholesterol itself as well as the 
conversion of cholesterol into primary bile acids [4, 5]. 
Several studies showed that hypercholesterolemia is a common 
feature of primary biliary cirrhosis (PBC) and other forms of the 
cholestatic liver disease [53]. This study looked at parameters such as 
ALP, AST and ALT as well as total bilirubin (TB), in addition to total 
proteins (TP), albumin and glucose, as markers of hepatic damage. 
Administration of the algal extracts to control animals did not induce 
any interference with the cholesterol metabolism as total and free 
cholesterol and it showed insignificant change either in liver 
parameters or in glucose level. 
Feeding rat’s atherogenic diet resulted in a significant elevation of 
plasma AST (67.67%), ALT (40.97%), ALP (115.29%), TB (40.91%), 
and glucose (59.72%) levels, whereas causes a reduction in TP 
(14.76 %) and albumin (27.12%) in the HC group compared to the 
corresponding values in normal control rats. 
The serum concentration of ALT, AST, ALP, TB, ALB and TP 
determines the functionality and cellular integrity of the liver [54]. 
The elevated enzyme activities in serum of hypercholesterolemic 
control rats reflect the alterations in serum membrane integrity 
and/or permeability [55]. 
Inconsistent with the present results, Sudhahar et al. [56] and Kim et 
al. [57], found that; the activities of ALT and AST tend to increase 
according to the exogenous cholesterol contents from diet and that 
hypercholesterolemia state significantly stimulate ALT and AST 
enzyme activities in the serum, resulting in increased enzyme 
leakage from hepatocytes. Excessive storage of fat in the liver effects 
on liver functions and increased the susceptibility to free radical 
attack in hypercholesterolemic rats resulting in liver damage. The 
increases in the serum activities of these enzymes was found to be 
directly proportional to the degree of cellular damage as described 
by Mhamed et al. [58] and Yadav et al. [59]. 
30-day post feeding rats high fat with cold, hot UFP or fluvastatin, 
the increase in the above parameters were significantly blocked and 
reduced when compared to corresponding values in the HC group. It 
was obvious that total protein and albumin levels were restored 
100% towards their normal values by treatment with cold or hot 
algal extracts of U. fasciata. The cold UFP showed the highest 
ameliorating effect, followed by hot extract while fluvastatin showed 
the lowest effect. Fluvastatin supplementation of hyper-
cholesterolemic rats resulted in significant reductions in the activity 
of ALP, AST and ALT activities as compared to the normal group. 
In consistent with the present finding, Arhoghro et al. [60], observed 
that, both cold and hot extracts increased the cellular membranes 
integrity and functionality of the liver as demonstrated by the 
reduction in the levels of ALT, AST, ALP, total bilirubin and elevation 
in albumin and TP contents in serum of HC-rats.  
Concerning glucose, a significant reduction in plasma glucose level 
was observed in all treated groups as compared to HC-group by 
38.18, 41.59 and 35.48%, respectively for cold, hot extracts and 
fluvastatin, as compared to HC-groups.  The glucose-lowering effect 
of SP may be attributed to gluconeogenesis and the regulation of 
serum lipid levels. The present results indicate the link between 
antihyperglycemic and hypolipidemic activities of aqueous extract of 
UFP [61]. Thus, it could be concluded that both hot and cold UFP 
extracts of U. fasciata normalized the levels of AST, ALT, ALP and TB 
as well as TP, albumin, and glucose. 
The imbalance of oxidation and reduction within the liver, known as 
oxidative stress, which is considered as an important mechanism of 
non-fatty liver disease (NAFLD), [62]. NAFLD is the emerging 
challenge in the field of human liver diseases [63]. 
As compared to control group, HC-group recorded a significant 
decrease in glutathione level by 60.34%. However, malondialdehyde 
(MDA) showed the dramatic elevation of 85.43%and also NO 
showed a marked increase by 300.29%; thus, hypercholesterolemia-
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induced Oxidative stress resulted in an elevation in hepatic MDA and 
NO, and in contrast a decline in hepatic GSH level, the non-enzymatic 
antioxidant defense system. 
Glutathione's highest concentration present in liver, it plays an 
important role in maintaining the intracellular redox equilibrium 
and protects tissues from oxidative stress. The depletion of GSH is 
associated with an increase in lipid peroxidation, the decrease in 
GSH level may be a consequence of enhanced utilization of this 
compound by the antioxidant enzymes, glutathione peroxidase and 
glutathione-S-transferase [64]. GSH is used in many metabolic and 
biochemical reactions, such as DNA synthesis, DNA repair, protein 
synthesis, prostaglandin synthesis, amino acid transport and 
enzymes activation [65]. 
Our findings are in accord with the experiment previously 
performed by Antoniades et al., [66] and Tall et al. [67], where it had 
been shown that ox-LDL-C can injure endothelial cells and lead to a 
decrease in nitric oxide synthase activity, thus inhibiting the 
production of NO, and also that, LDL-C can also significantly inhibit 
the production of NO from vascular endothelial cells, whereas HDL-C 
can enhance endothelial NO release. In the present study, high-fat 
diet significantly increased the hepatic NO level in hyperlipidemic 
rats, algal treatment caused decreased NO production, NO 
concentration showed significant decrease by 38.95, 69.46 and 
58.19% for cold SP and hot SP and fluvastatin respectively as 
compared to positive HC controls, a result that may be attributed to 
antioxidative effect of ulvan sulphated polysaccharide and to the 
increased HDL-C level and decreased LDL-C level.  
UFP treatments showed a marked surge in GSH concentration with 
the percentage of 134.78, 126.09 and 147.83%, respectively for cold, 
hot SP extracts and fluvastatin. While, MDA achieved significant 
decrease by 23.66, 31.07 and 28.75%, respectively for cold, hot 
extracts as well as fluvastatin reference drug, in comparison to 
positive control rats. 
Oxidative stress is one of the main mechanisms through which 
hypercholesterolemia exert its action. Too much lipid accumulated 
in the liver can damage the bio-membranes and the mitochondrial 
respiratory chain and increase β-oxidation of fatty acids that in turn, 
leads to an imbalance of oxidative phosphorylation and formation of 
free radicals. Oxidative stress also causes liver damage through the 
initiation lots of intermediate products with reactivity and 
cytotoxicity that subsequently leads to necrosis or apoptosis of cells. 
In addition, oxidative stress produces an inflammatory reaction 
through cell injury, causing the infiltration of the liver parenchyma 
by inflammatory cells. Attack of ROS against bio-membranes or 
lipoproteins leads to the oxidative destruction of polyunsaturated 
fatty acids by a process called lipid peroxidation, of which 
malondialdehyde (MDA) is a product and is, therefore, an indicator 
of oxidative stress in cells and tissues. This compound can increase 
the cross-linking of proteins, including cytoskeletal proteins [68]. 
MDA content can also be used as a biomarker of oxidative stress in 
subjects with hypercholesterolaemia [69]. 
Results from our study showed that UFP supplementation 
modulated antioxidant activities and lipid peroxide levels in the 
organs of hypercholesterolemic rats including the liver, and kidney; 
this might be attributed to the predominant component sugars in the 
hydrolysates of both SP extract polysaccharides; (rhamnose, xylose 
and galactose) for cold UFP, and (fucose, xylose and rhamnose) for 
hot UFP. UFP, therefore, could be protecting the cells of the liver 
from free radical damage. This hepatoprotective property of UFP may 
be due to its potent antioxidant effects. This corroborates the report of 
a previous study which showed that the activities of antioxidant 
enzymes and lipid peroxide levels in the liver of hypercholesterolemic 
rats were significantly reduced by UFP supplementation [70]. Thus 
UFP alleviates the oxidative stress by its inhibitory effect of lipid 
peroxidation by reducing the formation of MDA and enhances the 
antioxidant defense via increasing GSH retention. 
Decreased oxygen delivery and elevated stress occur within the 
adipocytes, resulting in cell death, initiation of the inflammatory 
response, and recruitment of macrophages to the site of injury. 
Macrophages accumulate in the adipose tissue and remodel the 
tissue. Exposure to fatty acids can initiate the inflammatory process 
on adipocytes and macrophages. The release of proinflammatory 
cytokines further activates the inflammatory process in nearby 
adipocytes, resulting in localized insulin resistance. Pro-
inflammatory cytokines, adipokines, and fatty acids also enter 
systemic circulation, causing insulin resistance in both liver and 
muscle [48]. 
The level of pro-inflammatory cytokines; TNF-α and CRP were all 
significantly higher in the HC-rats in comparison with the normal 
control group; high fat diet-rats showed a significant increase in pro-
inflammatory cytokines; TNF-α (73.19%) and CRP (61.52%) as 
compared to normal control rats. High cholesterol levels are 
frequently associated with increased soluble markers of systemic 
inflammation, such as C-reactive protein (CRP) [71]. Elevated 
cholesterol has also been shown to trigger the release of the 
inflammatory mediator C-reactive protein (CRP) [72].  
As compared to atherogenic rats (HC), treatment of HC-rats with 
both algal extracts showed a significant decrease in atherogenic 
inflammatory markers CRP and TNF-α with percentages decrease of 
21.04 and 16.82% respectively for cold extract, while hot extract 
recorded 27.21 and 18.21%, respectively.  
Concerning, MPO and IL-10 in HC-rats, we observed strong 
activation of several inflammation markers such as; 
myeloperoxidase MPO, as they are implicated in pathophysiological 
alterations. By algal treatment, the results clearly showed that the 
mean levels of detected IL-10 were significantly increased. Han et al. 
[73]; suggested that IL-10 induced scavenger receptor activity and 
uptake of pro-inflammatory modified LDL-C by macrophages, that 
may be efficient for removal of the harmful modified lipoproteins 
from the artery wall and disposal of cytotoxic free cholesterol, 
thereby decreasing inflammation and apoptosis in the lesion 
thereby, retarding early atherosclerotic lesion development. In 
addition, improvement in endothelial function and attenuation of 
endothelial activation may be attributed to a reduction in pro-
inflammatory markers of endothelial function; this may lead to a 
reduction in the progression of atherosclerosis and local production 
of the cytokines by inflammatory accumulated cells. 
The UFP-treatment normalized both ICAM-1 and VCAM-1 levels, as 
compared to negative control rats, whereas in comparison with 
diseased HC-rats, their treatment with cold, hot UFP extracts as well 
as fluvastatin, both CAMs were significantly reduced. On the basis of 
the presented data, both SP algal extracts of were observed to inhibit 
the expression of VCAM-1 and ICAM-1 as they known to be 
protective against the progression of atherosclerosis. These effects 
of UFPs may be due to antioxidative effects that reduced the 
oxidation of LDL-C to ox-LDL-C. Furthermore, VCAM-1 can also 
mediate the adhesion and migration of monocytes. These cells, 
located under the endothelium, become activated and differentiated 
into macrophages. Finally, these monocytes become foam cells via 
the aggregation of lipids. Additionally, the vascular smooth muscle 
cells gradually proliferate and migrate from the media to the intima, 
promoting further development of atherosclerotic lesions. Ox-LDL-C 
can also stimulate endothelial cells to produce adhesion molecules, 
increasing the atherogenicity [74]. 
The effects of hypercholesterolemia on renal function were assessed 
through measuring serum total urea and creatinine; high-fat diet 
intake caused significantly increase in levels of serum total urea and 
creatinine by 193% and 40%, respectively as compared to normal 
rats. This may be correlated with enhanced protein catabolism and 
accelerated amino acid deamination for gluconeogenesis as they are 
possible, an acceptable postulate to interpret the elevated levels of 
urea. The increase in serum urea level in hypercholesterolemic 
control group indicated impairment in the normal kidney function of 
the animal, as the mechanism of removing it from the blood, might 
have been affected. It may also be an indication of dysfunction at the 
glomerular and tubular levels of the kidney. It is well known that 
many biochemical and histopathological findings confirmed renal 
damage in hypercholesterolemia conditions [75]. 
Creatinine, synthesized in the liver, passes into the circulation where 
it is taken up almost entirely by the skeletal muscles. Its retention in 
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the blood is an evidence of kidney impairment as demonstrated by 
Wurochekke et al. [76]. In the present study, the elevated creatinine 
concentration is associated with the abnormal renal function. These 
data are in agreement with the previous study of Montilla et al. [77], 
who showed that hypercholesterolemia induced glomerular injury. 
The administration of both water algal SP extracts resulted in a 
detectable down-regulation of urea and creatinine levels. By 
comparison to HC-group, treatment of HC-rats with cold and hot 
algal extracts showed a significant decrease in total urea and 
creatinine with percentages decrease of 58.54 and 33.57%, 
respectively for cold extract, while hot extract recorded 60.37and 
31.43%, respectively. These results are in agreement with these 
found by Herreo et al. [78]. The reduced levels of urea and creatinine 
in the serum of HC-treated rats may imply that the algal extract 
interfered with creatinine metabolism and eventually excreted it 
from the blood. The significant reduction in creatinine, another 
product of protein metabolism upon SP extracts and drug 
administration to half the control value may be an indication of 
compromise of the renal function.  
These biochemical findings were associated with significant 
improvement in the cellular architecture of both liver and kidney. 
Histological investigations showed that the HC-rats displayed an 
important lipid droplet accumulation and both UFPs dramatically 
reduced in a dose-dependent manner the number of hepatocytes 
that contain lipid droplets. It was found that lipid droplets were 
observed only in the liver tissue of HC rats [79]. This could be 
attributed to lipid accumulation in the hepatocyte cell cytoplasm. 
Oxidized LDL induces the expression of scavenger receptors on the 
macrophage surface. These scavenger receptors promote the 
accumulation of modified lipoproteins, forming an early atheroma 
[80]. Ballooning of hepatocytes deformed cord arrangement, and 
disturbed sinusoids were seen Hepatocytes of HC rats showed 
severe degeneration with diffuse vacuolar degeneration and 
necrosis. Lipid droplets were observed only in the liver tissue of HC-
rats. This could be attributed to lipid accumulation in the hepatocyte 
cell cytoplasm. 
On the other hand,HC rats treated with both cold and hot SP extracts 
were improved with fewer endothelium injuries and less fat 
vacuoles, showed a considerable reduction in the pathological 
changes and exhibited an almost normal fig. as the control and the 
hydropic degeneration of the hepatocyte disappeared. The circular 
fat droplets in the cytoplasm decreased significantly, and only minor 
inflammatory cell infiltration was observed in portal areas. In 
addition, fluvastatin drug administered showed liver recovery 
included decrease signs of fatty liver with few fatty vacuoles. 
Light microscopy observations of HC-rats also revealed mild 
glomerular injury with mild vascular and inflammatory changes, 
signs of moderate vascular congestion, mesangial hyperplasia and 
dilatation of vascular lumen with no evidence of fat deposits (mild 
glomerular change), moderate tubular damage, that is, desquamated 
and/or vacuolated tubular epithelial cells. 
Treatment of HC-rats with algal extracts and fluvastatin showed, 
milder tubular injury, no glomerular or tubular alterations, no 
basement membrane thickening and fibrosis were discerned. 
Furthermore, normal histology of the glomerulus with well-spaced 
tubules, no congestion, and no inflammation was detected. 
This ameliorative effect might be attributed to the anti-
inflammatory, antioxidant and hypolipidemic effect of sulphated 
polysaccharides (SP) of U. fasciata that restored renal 
histopathology to its normal appearance. 
CONCLUSION 
It could be concluded that hot and cold UFP ameliorated/ 
normalized all the NAFLD or CKD (Chronic kidney disease), risk 
parameters induced by lipidemic-oxidative stress.  
On the evaluation of the integrity of HC liver and kidney following 
consumption of UFP, the results showed that the integrity of the 
liver and kidney was preserved as there were no significant 
alterations in the levels of kidney and liver function. The 
ameliorative effect of both algal extracts was assessed by measuring 
different liver and kidney parameters that were well proven by the 
histological findings; these results suggest that UFP may be 
beneficial in ameliorating hypercholesterolemia-associated liver and 
kidney injury. Therefore, Sulphated polysaccharides (SP) can be 
regarded as potential anti-peroxidative, atheroprotective, hypolipidemic, 
and antiatherogenic agents, and may be used in the protection of 
ROS/free radical-induced oxidative damage, hyperlipidemia/ 
dyslipidemia and atherosclerotic complications including CHD.  
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